Connect with us

News

Insider Insight: Oriana Papin-Zoghbi, CEO and co-founder of AOA Dx

Published

on

AOA Dx was founded in 2020 with the aim of giving women access to the most innovative early detection platform in their fight against cancer. Femtech World caught up with CEO and co-founder Oriana Papin-Zoghbi for our latest Insider Insight piece.

What is your morning routine?

I try to wake up before my toddler to enjoy a quiet morning with a cup of coffee, but most days, she’s an early riser, and we jump straight into breakfast. We have breakfast as a family, and then I take her to school—this quality time with her is one of my favorite parts of the day.

A few days a week, I make an effort to get up extra early to fit in a workout, which is essential for me. Once I’m back and ready to start my workday, I check my Notion dashboard to organize my tasks before diving into emails. This helps set me up for success and helps me prioritize tasks for the day.

Which technology could you not live without?

I couldn’t live without Notion, it’s like my second brain. I’m a strong believer in David Allen’s Getting Things Done method, a personal productivity approach that redefines how you manage both life and work. It emphasizes that when your mind is overloaded, you can’t think as clearly or effectively, so staying organized is key

How do you relax?

I’m still working on getting better at relaxing, but as someone who’s always striving to get things done, it can be a challenge. The best way for me to unwind is by taking walks with my family and our dog. We love strolling around the city and spending time at the park.

Which quote resonates with you?

If you can dream it, you can do it’ – Walt Disney. As an immigrant from a humble background, this quote deeply resonates with me. My family worked incredibly hard, dreamed big, and made it happen. It’s a philosophy I’ve always embraced.

What is the best thing about your job?

The best part of my job is the incredible people I work with and our shared mission to create a better future for ovarian cancer patients. This mission drives me every day. I feel truly fortunate to be on this journey with my co-founders, team, investors, advisors, and everyone helping us make early detection a reality.

What keeps you motivated?

Indignation on the status of women’s health,  especially now that I have a daughter and have experienced my own challenging journey to start a family. 

What is the most important lesson you have learned on your start-up journey?

The most important lesson I’ve learned on my startup journey is that hiring is everything. Bringing on the right people can make or break your company. I heard this advice early on, but it wasn’t until I experienced it firsthand that I truly understood how crucial it is.

What advice would you give to your younger self?

Work for people, not just companies. In the early stages of your career, it’s essential to soak up as much knowledge as possible, as traditional education only takes you so far. Seek out companies with strong leaders who can mentor you during these formative years. Instead of chasing the trendiest company, focus on finding the right people, great managers and colleagues, who will support your growth and development.

What is something you wish you could experience again for the first time?

My wedding. Throughout my life, I’ve moved around the world, and my husband has also experienced his share of relocations. Our friends and family are scattered across different corners of the globe, so our wedding was the one occasion when everyone came together in one place. I felt incredibly grateful to have all of them there to celebrate with us. It was one of the most special moments of my life, and I cherished being surrounded by the people I love most.

What is your greatest achievement since establishing AOA?

Building our team has been our greatest achievement and the most significant learning curve. While we’ve had success in raising capital, publishing papers, de-risking our technology,  making progress on our milestones, etc, none of this would have been possible without our team.

My co-founders, Alex, Anna, and I have worked diligently to assemble a phenomenal group of individuals who are truly passionate and committed to AOA.

Diagnosis

Lung cancer drug shows breast cancer potential

Published

on

Ovarian cancer cells quickly activate survival responses after PARP inhibitor treatment, and a lung cancer drug could help block this, research suggests.

PARP inhibitors are a common treatment for ovarian cancer, particularly in tumours with faulty DNA repair. They stop cancer cells fixing DNA damage, which leads to cell death, but many tumours later stop responding.

Researchers identified a way cancer cells may survive PARP inhibitor treatment from the outset, pointing to a potential way to block that response. A Mayo Clinic team found ovarian cancer cells rapidly switch on a pro-survival programme after exposure to PARP inhibitors. A key driver is FRA1, a transcription factor (a protein that turns genes on and off) that helps cancer cells adapt and avoid death.

The team then tested whether brigatinib, a drug approved for certain lung cancers, could block this response and boost the effect of PARP inhibitors. Brigatinib was chosen because it inhibits multiple signalling pathways involved in cancer cell survival.

In laboratory studies, combining brigatinib with a PARP inhibitor was more effective than either treatment alone. Notably, the effect was seen in cancer cells but not normal cells, suggesting a more targeted approach.

Brigatinib also appeared to act in an unexpected way. Rather than working through the usual DNA repair routes, it shut down two signalling molecules, FAK and EPHA2, that aggressive ovarian cancer cells rely on. FAK and EPHA2 are proteins that relay survival signals inside cells. Blocking both at once weakened the cells’ ability to adapt and resist treatment, making them more vulnerable to PARP inhibitors.

Tumours with higher levels of FAK and EPHA2 responded better to the drug combination. Other data link high levels of these molecules to more aggressive disease, pointing to potential benefit in harder-to-treat cases.

Arun Kanakkanthara, an oncology investigator at Mayo Clinic and a senior author of the study, said: “This work shows that drug resistance does not always emerge slowly over time; cancer cells can activate survival programmes very early after treatment begins.”

John Weroha, a medical oncologist at Mayo Clinic and a senior author of the study, said: “From a clinical perspective, resistance remains one of the biggest challenges in treating ovarian cancer. By combining mechanistic insights from Dr Kanakkanthara’s laboratory with my clinical experience, this preclinical work supports the strategy of targeting resistance early, before it has a chance to take hold. This strategy could improve patient outcomes.”

Continue Reading

Insight

Higher nighttime temps linked to increased risk of autism diagnosis in children – study

Published

on

Nighttime temperatures during pregnancy may be linked to a higher chance of an autism diagnosis in children, a recent study suggests.

The research tracked nearly 295,000 mother-child pairs in Southern California from 2001 to 2014 and linked warmer overnight temperatures with higher risk in early and late pregnancy.

Children of mothers exposed to higher than typical nighttime temperatures during weeks one to 10 of pregnancy had a 15 per cent higher risk of an autism diagnosis.

Exposure during weeks 30 to 37 was linked to a 13 per cent higher risk.

 Lead author David Luglio, a post-doctoral fellow at Tulane University, said: “A key takeaway is that we identified specific windows when a mother and her developing child can be most affected by exposures to higher nighttime temperatures.

“This is critical and hopefully can help mothers prepare accordingly.”

The study is described as the first to examine how temperature may affect fetal neurodevelopment, the process by which a baby’s brain and nervous system form during pregnancy.

Extreme temperatures linked to increased risk were classified as above the 90th percentile, meaning 3.6°F hotter than average, and the 99th percentile, 5.6°F above average.

The association held even after researchers accounted for factors such as neighbourhood conditions, vegetation and fine-particle air pollution.

The study could not account for other factors such as access to air conditioning. Researchers did not find the same association with daytime temperatures, potentially because people spend more time away from home during the day.

“Heat waves are becoming more frequent, and people may only think of the dangers of daytime heat exposure,” said Mostafijur Rahman, assistant professor of environmental health sciences at Tulane University.

“These results indicate a strong association between high nighttime temperatures during pregnancy and autism risk in children and show that we need to think about exposure to heat around the clock.”

The study did not examine how higher temperatures at night might affect prenatal development, though Luglio said it is possible that warmer nights disrupt sleep for pregnant mothers.

Previous research has suggested insufficient sleep during pregnancy may be linked to a higher risk of neurocognitive delays in children.

“Extreme heat exposure during pregnancy has been linked to a range of adverse health outcomes, including prenatal neurodevelopment delays and complications with an embryo’s development of a central nervous system,” Luglio said.

“The goal of our study was to specifically explore the link between prenatal heat exposure and autism diagnoses for the first time.”

Continue Reading

Entrepreneur

Kindbody unveils next-gen fertility platform

Published

on

Kindbody has launched a fertility platform integrating AI with clinical care and patient support for employers and health plans.

The platform will enter a pilot with select Kindbody employer clients in 2026, covering over three million lives, ahead of wider availability in 2027.

Building on the company’s clinical model, the platform aims to improve outcomes and cost efficiency across family-building journeys. It connects Kindbody-owned clinics, partner clinics and an integrated clinical app.

The app offers virtual care across conception, pregnancy and reproductive health, extending through the menopause transition.

Launch features include updates in medication management, third-party reproduction, adoption, pregnancy, men’s health and global programme design.

David Stern, chief executive of Kindbody, said: “With our next-generation fertility platform, Kindbody is redefining what comprehensive, intelligent and affordable family-building care looks like for employers, health plans and patients.

“By unifying best-in-class clinical care, AI-driven intelligence and whole-person support, we are making it easier and more cost-effective for more people to build the families they envision.”

Kindbody has expanded access via its national network of IVF centres, including IVIRMA, Inception Fertility and Ivy Fertility.

A new Fertility Medication Portal is designed to streamline authorisations so medicines can be dispensed on time, giving patients visibility from prescription to coverage, pharmacy fulfilment and delivery tracking.

Through KindMan, men’s health education, digital resources and integrated clinical care are expanding, including hormone management programmes.

Services cover andropause (age-related testosterone decline), erectile dysfunction, low testosterone and other male reproductive conditions.

Specialist fertility care includes semen analysis, diagnostic testing, male hormone panels, genetic testing, surgical sperm extraction and sperm cryopreservation.

Launching in the second quarter, a pregnancy support app will act as a digital companion for expecting and new parents, with resources, interactive tools and clinical assessments to identify social drivers of health and mental health needs during pregnancy and beyond.

Kindbody’s physician-led menopause programme provides consultations with board-certified obstetricians and gynaecologists to diagnose, treat and manage menopausal symptoms, including hormone replacement therapy where appropriate, with support from nutritionists, mental health therapists and pelvic floor specialists.

AI and analytics will be embedded across the care journey. An AI care navigator will guide employees from benefit activation through intake, triage and scheduling.

Tools will track benefits and treatment plans, showing coverage and expected out-of-pocket costs at each step.

AI-supported scribing will assist clinicians with documentation, and a predictor tool will estimate a patient’s likelihood of having a baby across different treatment paths.

In 2027, Kindbody plans a savings model for eligible large employers that it says will guarantee lower total fertility spend while improving clinical efficiency and patient experience.

Continue Reading

Trending

Copyright © 2025 Aspect Health Media Ltd. All Rights Reserved.